We’re experiencing issues with our datasets and search. We apologise for any inconvenience while we work to fix this.
AREXVY GlaxoSmithKline Australia Pty Ltd
Product name
AREXVY
Accepted date
Oct-2025
Active ingredients
recombinant respiratory syncytial virus pre-fusion F protein
Summary of proposed indication
AREXVY is is a vaccine proposed for active immunisation for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV) in adults 18 years of age and older.
The use of this vaccine should be in accordance with official recommendations.
The use of this vaccine should be in accordance with official recommendations.
Application type
C (new indication)
Publication date
Oct-2025